Tibet Rhodiola Pharmaceutical Holding Co. (SHA:600211)

Market Cap	13.19B +11.2%
Revenue (ttm)	2.99B +6.3%
Net Income	967.36M -4.0%
EPS	3.00 -4.1%
Shares Out	318.32M
PE Ratio	13.82
Forward PE	n/a
Dividend	1.76 (4.24%)
Ex-Dividend Date	May 22, 2026

Volume	1,528,249
Average Volume	3,361,383
Open	41.31
Previous Close	41.45
Day's Range	40.66 - 41.60
52-Week Range	35.41 - 57.98
Beta	0.30
RSI	43.43
Earnings Date	Apr 29, 2026

About SHA:600211

Tibet Rhodiola Pharmaceutical Holding Co. produces and sells pharmaceutical products in China and internationally. The company offers modern Tibetan Medicines, including Nodikang capsules and granules, snow mountain golden arhat pain relief film, and ten-flavor Tida capsules; modern Chinese medicines, such as children Shuangqing granules, lipid clearing capsules, ginseng and zhi capsules, puyu capsules, and epilepsy flat film; and recombinant human brain natriuretic peptide for injection. It also provides isosorbide mononitrate sustained-releas...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 671
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600211

Financial Performance

In 2025, SHA:600211's revenue was 2.98 billion, an increase of 6.23% compared to the previous year's 2.81 billion. Earnings were 937.93 million, a decrease of -10.78%.